oral semaglutide cardiovascular outcomes soul trial results 2024 2025 Oral Semaglutide in High-Risk Type 2 Diabetes: Cardiovascular Benefit Confirmed in the SOUL Trial Clinical Effectiveness and Safety of – soul trial oral semaglutide cardiovascular

It is approved specifically for visceral adiposity associated with HIV-related lipodystrophy, but the clinical data on its mechanism extends beyond that narrow indication

Experiencing a bad taste in your mouth whilst taking GLP-1 medications is an uncommon but recognised side effect that can affect some patients during treatment

Questions to Ask Your Healthcare Provider It can be helpful to prepare questions ahead of time to ensure you get the answers you need

Its vital for women to know that they dont have to face GLP-1 RA side effects alone

Our guide covers the similarities and differences between Wegovy, Ozempic and Mounjaro (another similar weight loss injection)